Blood endocan as a biomarker for breast cancer recurrence.

IF 2.2 4区医学 Q3 ONCOLOGY

Cancer Biomarkers Pub Date : 2024-01-01 DOI:10.3233/CBM-240034

Kentaro Daiki, Yoko Kanada, Aya Nagata, Kanae Taruno, Katsuhide Igarashi, Toshiko Yamochi, Hirotaka Ota, Fumiaki Sato, Seigo Nakamura, Yoshinori Kato

{"title":"Blood endocan as a biomarker for breast cancer recurrence.","authors":"Kentaro Daiki, Yoko Kanada, Aya Nagata, Kanae Taruno, Katsuhide Igarashi, Toshiko Yamochi, Hirotaka Ota, Fumiaki Sato, Seigo Nakamura, Yoshinori Kato","doi":"10.3233/CBM-240034","DOIUrl":null,"url":null,"abstract":"Background: Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.Objective: This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.Methods: Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).Results: Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.Conclusions: Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":" ","pages":"145-154"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495321/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-240034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.

Objective: This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.

Methods: Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).

Results: Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.

Conclusions: Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.

查看原文本刊更多论文

作为乳腺癌复发生物标志物的血液内切酶。

背景据报道，内切酶对乳腺癌患者有负面影响，并可从患者血液中检测到：本研究旨在探讨与现有的肿瘤标志物相比，测定ESM1高表达的乳腺癌患者血液中的内切酶是否能成为检测术后复发的有效工具：方法：在乳腺癌小鼠模型的肿瘤切除前后采集血液，测量内切酶的水平，同时用无创荧光成像技术观察转移性复发。在临床环境中，16 名乳腺癌患者在肿瘤切除前后抽取了血液，并评估了肿瘤切除术对血液内切酶水平的影响。此外，还测量了 20 名术后复发患者的血液内切酶，并将其内切酶阳性率与血清癌胚抗原（CEA）或癌抗原 15-3 （CA15-3）的阳性率进行了比较：结果：我们的临床前和临床实验显示，血液中的内切酶水平反映了肿瘤负荷。此外，在 CEA 或 CA15-3 检测阴性的术后复发患者中，超过 60% 的患者内切酶呈阳性：我们的研究结果支持内切酶在乳腺癌患者中检测乳腺癌复发的临床意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biomarkers ONCOLOGY-

CiteScore

5.20

自引率

3.20%

发文量

195

审稿时长

3 months

期刊介绍： Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.